Treatment-free remission following frontline nilotinib for CML-CP: five-year update

Prof. Giuseppe Saglio

Five-year follow-up results of the ENESTfreedom trial support the efficacy and safety of attempting treatment-free remission following at least three years upfront nilotinib for chronic myeloid leukemia in chronic phase.